Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona +57 locations
Conditions: Conventional Chondrosarcoma
Register for Updates
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399
Recruiting
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/09/2025
Locations: Research Site, La Jolla, California +284 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Enabling Genomic Testing in Cancer of Unknown Primary
NCT06695494
Recruiting
Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP mo... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/08/2025
Locations: The Christie NHS Foundation Trust, Manchester, Greater Manchester +5 locations
Conditions: Cancer of Unknown Primary, Neoplasm, Unknown Primary
Register for Updates
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT02813135
Recruiting
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019). The aims of the trial are: 1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and 2. To explore first signals of activity in a molecularly enriched study p... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/08/2025
Locations: Rigshospitalet, Copenhagen, Not set +20 locations
Conditions: Pediatric Cancer
Register for Updates
Anti-viral Action Against Type 1 Diabetes Autoimmunity
NCT06452654
Recruiting
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or placebo from age 6 months. The study is an investigator initiated, randomized, controlled, multicentre, multinational, primary prevention trial for children at increased risk of type 1 diabetes. The primary objective is to determine whether vaccination of children with elev... Read More
Gender:
ALL
Ages:
Between 3 months and 4 months
Trial Updated:
01/08/2025
Locations: University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven, Leuven, Not set +7 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
NCT03369821
Recruiting
Type 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). It is not fully understood what causes this type of diabetes and why there is variation in age of onset and severity between people who develop the disease. The aim of this work is to study very unusual people who develop T1D extremely young, as babies under 2 years of age (EET1D). The investigators think that, for the condition to have developed that ear... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
01/07/2025
Locations: Benaroya Research Institute, Seattle, Washington +3 locations
Conditions: Type1 Diabetes Mellitus
Register for Updates
Stimulated Glucagon As a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
NCT05616273
Recruiting
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels and need to have insulin injections to lower blood glucose levels. Whilst high blood sugar level is a problem for people with Type 1 diabetes, taking insulin medication to lower sugar levels, delayed meals and exercise can all result in dangerously low blood sugar levels (... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
01/07/2025
Locations: Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon
Conditions: Type 1 Diabetes, Hypoglycemia
Register for Updates
Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE)
NCT06478121
Recruiting
This observational 'recruit by genotype' study aims to provide insights into the cellular and molecular pathways underlying beta cell disorders and their physiological consequences. Eligible individuals are those with and without a pathogenic genetic variant, acting as case and control, respectively. Using a "recruit by genotype" approach, the researchers will perform detailed and specific analysis according to the individual's genetic variant. The study's main aims are to : 1) identify and des... Read More
Gender:
ALL
Ages:
Between 6 years and 99 years
Trial Updated:
01/07/2025
Locations: Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon
Conditions: Diabetes Mellitus, Monogenic Diabetes, Hyperinsulinism
Register for Updates
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
NCT03188796
Recruiting
In the VITdAL-ICU trial using a large oral dose of vitamin D3 in 480 adult critically ill patients, there was no benefit regarding the primary endpoint hospital length of stay. However, the predefined subgroup with severe vitamin D deficiency (25(OH)D ≤ 12ng/ml) had significantly lower 28-day mortality (36.3% placebo vs. 20.4% vitamin D group, hazard ratio (HR) 0.52 (0.30-0.89), number needed to treat = 6). Therefore, high-dose vitamin D3 in a population of severely vitamin D deficient criticall... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/07/2025
Locations: LKH Enzenbach, Enzenbach, Not set +17 locations
Conditions: Critical Illness, Vitamin D Deficiency, Covid19
Register for Updates
Surgical Treatments for Postamputation Pain
NCT05009394
Recruiting
This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois +8 locations
Conditions: Amputation Neuroma, Phantom Limb Pain, Pain, Neuropathic, Pain, Nerve, Residual Limb Pain
Register for Updates
The Euro-CRAFT Registry
NCT05805462
Recruiting
The Euro-CRAFT Registry is a prospective, multicentric, international registry of patients undergoing functional assessment of the coronary microcirculation using the continuous thermodilution technique. Angina and quality of life questionnaires (Seattle Angina Questionnaire 19 - SAQ19, ORBITA app) will be obtained at baseline, at 6 months, and 1-year follow-up. Clinical follow-up will be performed at 1 year (optionally until 5 years).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: OLV Ziekenhuis Aalst, Aalst, Not set +18 locations
Conditions: Coronary Microvascular Disease
Register for Updates
A Study of Probiotics in IgA Nephropathy
NCT06767592
Recruiting
IgA nephropathy (IgAN) occurs when a specific form of the IgA antibody lodges on the kidneys and causes damage, which may lead to kidney failure. This form of IgA is likely to come from the gut and the upper airways. Recent studies have shown that the bacteria that live in these areas may be different in IgAN. We think that the interaction between these and the immune system triggers production of the IgA that leads to kidney damage. We will examine these bacteria in detail, and test whether a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, Leicestershire
Conditions: IgA Nephropathy
Register for Updates